Leyden Labs
Develops nasal spray-based respiratory virus prevention products, with a current focus on addressing influenza protection beyond traditional vaccines.
Overview
Leyden Labs is a biotechnology company developing a nasal spray approach aimed at preventing respiratory infections, with its current public funding narrative centered on influenza. The company is positioned around a non-traditional prophylactic format that could complement or challenge decades of flu vaccine development. Its target market is respiratory disease prevention, including public health use cases where broader or easier-to-administer protection is valuable. Leyden Labs raised €40M in a round backed by the Gates Foundation, highlighting philanthropic interest in alternatives to existing flu-prevention tools.
Funding History
Gates Foundation backs Leyden Labs’ €40M raise: Can a nasal spray do what 80 years of flu vaccines couldn’t
Frequently Asked Questions
- How much funding does AI Funding track for Leyden Labs?
- AI Funding tracks €40M for Leyden Labs across 1 funding round in this database.
- Who are Leyden Labs's investors?
- Leyden Labs's investors include EIC Fund, Bill & Melinda Gates Foundation, Invest-NL, ClavystBio.
- What does Leyden Labs do?
- Leyden Labs is a biotechnology company developing a nasal spray approach aimed at preventing respiratory infections, with its current public funding narrative centered on influenza. The company is positioned around a non-traditional prophylactic format that could complement or challenge decades of flu vaccine development. Its target market is respiratory disease prevention, including public health use cases where broader or easier-to-administer protection is valuable. Leyden Labs raised €40M in a round backed by the Gates Foundation, highlighting philanthropic interest in alternatives to existing flu-prevention tools.
- Where is Leyden Labs headquartered?
- Leyden Labs is headquartered in Amsterdam, Netherlands.
Investors
Related Insights
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
Track 395+ AI funding rounds—investors, valuations, and deal sizes from pre-seed to IPO. Updated daily so you never miss a round.
An in-depth look at how AI-focused venture capital operates — from fund structure and deal sourcing to due diligence, portfolio management, and exit strategies in the AI era.